Journal article

Evaluation of Quantiferon (R)-Monitor as a biomarker of immunosuppression and predictor of infection in lung transplant recipients

Bradley J Gardiner, Sue J Lee, Yvonne Cristiano, Bronwyn J Levvey, Lucy C Sullivan, Gregory Snell, Anton Y Peleg, Glen P Westall

TRANSPLANT INFECTIOUS DISEASE | WILEY | Published : 2021

Abstract

BACKGROUND: Optimizing immunosuppression in lung transplant recipients (LTR) is crucially important in minimizing the risk of infection and rejection. Quantiferon®-Monitor (QFM) is a candidate immune function biomarker which has not yet been rigorously evaluated in the lung transplant setting. The aim of this prospective cohort study was to explore relationships between QFM results, immunosuppression, and infection/rejection in LTR. METHODS: QFM, which measures interferon-γ after stimulation with innate and adaptive immune antigens, was tested before and at 2, 6, 12, 24 and 52 weeks post-transplant. Immunosuppression relationships were assessed with linear mixed effects models. Clinical outc..

View full abstract

University of Melbourne Researchers

Grants

Awarded by National Health and Medical Research Council of Australia


Funding Acknowledgements

This work was supported by the National Health and Medical Research Council of Australia (grant number GNT1150351) and the Lungitude Foundation. Study support and assays were provided by Qiagen